Search

everythinglearnresearchcommunity

for

Search:↓

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

The user is generally happy with their hair transplant results but has concerns about graft density and placement, particularly on the left temple and hairline. They are using finasteride and minoxidil inconsistently, plan to add Priorin, and are considering microneedling and PRP sessions for future care.

The conversation discusses the growing acceptance of hair systems/toupees on social media, particularly on TikTok, with mixed personal experiences. Some users prefer treatments like Minoxidil and finasteride despite side effects.

A 26-year-old is experiencing unexpected hair shedding on the scalp, eyebrows, eyelashes, and body, along with greasy skin, and has decided to see a doctor. They are seeking advice and support.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A person shared their hair regrowth journey using HIMS topical treatments with finasteride, minoxidil, hormone replacement therapy (HRT), and microneedling. They also discussed their transition as a transgender woman and the positive impact of HRT on hair recovery.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

A user was prescribed a topical treatment for hair loss including Latanoprost, Minoxidil, Dutasteride, Hydrocortisone, and Progesterone, after using an oral Minoxidil and Finasteride combo without significant results. Concerns were raised about the long-term use of hydrocortisone, with suggestions to consult a doctor regularly.

Stemoxydine is more expensive than minoxidil and finasteride, costing $50-$150 per month. The discussion questions why the cost is higher despite efficacy.

A user is developing an AI-powered app for hair loss that includes features like hair loss stage detection and hairline tracking. They seek feedback to ensure the app is useful and emphasize privacy and affordability.

The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

A 27-year-old male started using finasteride in February 2023 for hair loss, experiencing significant progress with no side effects. He is considering adding oral minoxidil or getting a hair transplant, but is concerned about the cost in the Netherlands.

A user shared their experience with hair loss treatments, including finasteride, minoxidil, and RU58841, which improved their hair from a diffuse NW3 to a solid NW2 - 2.5. They noticed significant changes in how people treated them after regrowing their hair, suggesting that attractiveness can greatly impact social interactions and opportunities.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The conversation is about finding an online pharmacy within the EU that sells oral minoxidil and finasteride. Recommendations include Justhair and Minoxidiexpress.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

A 21-year-old expresses feeling alone and invalidated in his struggle with hair loss, seeking empathy from others. Some users share similar feelings, while one mentions making progress with dutasteride and minoxidil treatments and considering a hair transplant.

A 34-year-old male has been using a topical minoxidil and finasteride solution for hair loss and was prescribed oral finasteride by a dermatologist. He questions the necessity of monthly consultations since the prescription remains unchanged.

A British man's death at a Turkish hair transplant clinic raised safety concerns about such clinics. Users discussed risks of cheaper clinics and suggested alternatives like Thailand, Korea, and Colombia.

An 18-year-old is using a high-dose treatment for hair loss, including 2.5 mg dutasteride, topical minoxidil, and injectable GHK-Cu, despite minimal hair loss. Many users suggest reducing the dutasteride dose due to potential side effects and recommend starting with finasteride instead.

The conversation humorously discusses the journey of deciding to use finasteride for hair loss, with a focus on a funny Facebook post. It also touches on the idea of promoting finasteride use to future generations.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

A user's experiences with hair loss treatments, including finasteride and hair transplants, in relation to another person who has been publicly vocal about their own hair loss struggles. People have shared opinions on this other person's treatment choices and the results of their hair transplant.

The conversation discusses potential hair loss treatments, including hair cloning, setipiprant, and topical finasteride, questioning their availability and effectiveness as permanent cures. The user is inquiring about the release dates and efficacy of these treatments.